Connect your AI

Bioventus BVS Debt Issuance Costs

Debt Issuance Costs at other companies

Orthofix Medical Inc.OFIX

$24K-95.3%

Zimmer Biomet HoldingsZBH

$0-100%

Other financials

Income statement

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: Bioventus’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bioventus's debt issuance costs?: Bioventus (BVS) reported debt issuance costs of $174.25K in Q4 2025.
How has Bioventus's debt issuance costs changed year-over-year?: Bioventus's debt issuance costs decreased by 40.9% year-over-year, from $295K to $174.25K.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.